As attention turns to humanity’s next chapter beyond low Earth orbit, the Artemis II program continues to symbolize how far space exploration has come—and how complex it is becoming.
The mission, designed to carry astronauts around the Moon and safely return them to Earth, underscores a central reality of modern spaceflight: precision, protection, and operational continuity are no longer optional. They are foundational.
What the “Buzz”
Our Bullboards have up to 2 million pageviews a day. Get the inside scoop on conversations around the most significant trends and stock appreciations in our weekly wrap up.
Get “Buzz on the Bullboards” delivered to your inbox every third Thursday!
Buzz on the Bullboards | Sign Up Here
That evolving reality is shaping not only national space agencies, but also publicly traded companies positioning themselves at the intersection of exploration, security, and advanced technology. This week, three Toronto Stock Exchange-listed companies that made news for developments that highlight how innovation, defence priorities, and strategic alignment are influencing the market.
Turning space domain awareness into action
Against the backdrop of expanding orbital traffic and growing geopolitical tension in space, MDA Space (TSX:MDA, Forum) made headlines at the 41st Space Symposium in Colorado Springs with the unveiling of MDA Midnight, a next-generation space control platform aimed at defence and security organizations.
MDA Midnight is designed as a maneuverable spacecraft capable of high-reliability rendezvous and proximity operations (RPO). Its core mission is to detect, identify, counter, and deter threats to critical space assets and orbital infrastructure—an increasingly important task as satellites play a central role in national security, communications, navigation, and economic activity.
Beyond threat deterrence, MDA Midnight is built as a multi-role platform. It can support existing military missions through on‑orbit surveillance, satellite relocation, and even satellite refuelling, reflecting a broader trend toward sustainability and resilience in space operations. The spacecraft is equipped with both active and passive payload capabilities, alongside advanced robotics, allowing operators to convert raw space domain awareness into actionable decision-making.
This announcement arrives at a time when nations are reassessing their vulnerability in orbit. A recent Global Counterspace Capabilities report from the Secure World Foundation points to a growing interest among countries in developing so-called “bodyguard satellites” to protect high-value space assets. Canada, for its part, has formally recognized space as a key sovereign capability, reinforcing the relevance of domestically developed space defence solutions.
The initial MDA Midnight mission profile reflects this demand. It is designed to rendezvous with multiple collaborative assets in low Earth orbit and deploy a range of protective and defensive capabilities, including:
- On-orbit inspection and reporting of satellite status
- Detection, attribution, and mitigation of electronic countermeasures
- Cooperative satellite capture and release using RPO capabilities
- De-orbiting of non-operational customer assets
On the ground, operations will be supported by flight controller teams with experience spanning over 100 free-flyer captures and decades of robotic operations in orbit. Select customers may also operate MDA Midnight through MDA Space’s established Mission Control Centre. The platform leverages recent investments across MDA’s broader product suite, including MDA Skymaker commercial robotics and the MDA Aurora satellite bus, positioning it as a mission-ready solution that can be rapidly configured and deployed.
Preclinical results point toward clinical potential
While MDA Space focuses on the frontier above the Earth, Theralase Technologies (TSXV:TLT, Forum) is pushing boundaries at the cellular level. The clinical-stage pharmaceutical company announced compelling preclinical results for X-Ray-activated Rutherrin in an animal model of Muscle Invasive Bladder Cancer (MIBC).
In the orthotopic MIBC study, Kaplan–Meier survival analysis demonstrated a 100% complete response rate among animals treated with X-Ray-activated Rutherrin. Every treated animal remained cancer-free at the conclusion of the study—an outcome not observed in either control group.
Animals receiving radiation only experienced partial benefit, with survival declining steadily over time. Individuals in this group succumbed to disease between 25 and 70 days. Untreated animals fared worse, perishing between 20 and 23 days, consistent with aggressive tumor progression.
These findings build on previously reported data but add an important dimension: durability. By demonstrating both complete response and sustained survival, the study provides stronger validation of Rutherrin’s mechanism and therapeutic potential. According to the company, this preclinical success lays the groundwork for further clinical development and evaluation in humans.
For Theralase, whose research centers on energy-activated small molecules aimed at destroying cancer, bacteria, and viruses while minimizing collateral damage, the results represent a meaningful step forward in addressing conditions with limited treatment options.
Business realignment south of the border
Completing this week’s trio is Almonty Industries (TSX:AII, Forum), a global producer of tungsten—a critical input for defence, aerospace, and advanced manufacturing industries. The company announced it is relocating its corporate headquarters from Toronto to Dillon, Montana, marking a notable shift in its strategic footprint.
The relocation reflects Almonty’s deepening alignment with U.S. defence and industrial priorities, as governments increasingly seek secure, transparent, and Western-aligned supply chains for critical minerals. By moving closer to U.S. government agencies, defence contractors, and industrial partners, Almonty aims to reinforce its position as one of the leading U.S.-aligned producers of tungsten.
The move follows a period of significant corporate activity, including Almonty’s Nasdaq listing and US$90 million oversubscribed IPO in July 2025, a US$129 million follow-on financing in December 2025, and the acquisition of Montana’s Gantung Tungsten Project, which is expected to restart production this year.
Almonty has also strengthened its defence ties through a partnership with American Defense International, participation in the Department of Defense-sponsored Critical Minerals Forum, and congressional recognition for its role in supporting mineral independence. The appointment of former senior U.S. Army generals to its board further underscores the company’s emphasis on national security expertise and geopolitical alignment, particularly as Western nations seek to reduce reliance on Chinese-controlled tungsten supply chains.
On the horizon ….
From orbital defence systems to cancer therapeutics and critical mineral security, this week’s news highlights the diverse ways innovation and geopolitics are intersecting in the public markets. MDA Space, Theralase Technologies, and Almonty Industries each reflect broader structural shifts—whether in space governance, medical science, or resource independence—that can have lasting implications.
For readers and investors alike, developments like these serve as a reminder that markets are shaped not just by earnings, but by technology roadmaps, regulatory trends, and strategic positioning. With that in mind, staying informed—and deepening due diligence into news-making stocks—can help ensure portfolios remain aligned with an increasingly complex global landscape.
Get “Buzz on the Bullboards” delivered to your inbox every other Thursday!
Buzz on the Bullboards | Sign Up HereFor previous editions of Buzz on the Bullboards, click here.
Join the discussion: Find out what everybody’s saying about these stocks on Stockhouse’s stock forums and message boards.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.